{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T16:34:59Z","timestamp":1756571699262,"version":"3.40.5"},"reference-count":35,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T00:00:00Z","timestamp":1583798400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Outcome for relapsed acute myeloid leukemia (AML) is poor. Cladribine has activity in AML, and an enhancing effect on other cytostatic drugs thus may help overcome resistance. Here, we present the final analysis of our phase II trial evaluating safety and efficacy of cladribine, cytarabine, and idarubicin (CAI) in relapsed AML.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with relapsed AML after at least 6\u00a0months remission received two courses of CAI. After 9 patients, prolonged neutropenia prompted protocol change (omission of idarubicin in 2nd course and dose\u2010reduction of cytarabine). Primary endpoints were remission rate and safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty patients received treatment, fourteen one, and six two courses CAI\/CA. After first course, complete remission (CR\/CRi) was achieved in 60%. Most frequent toxicity was infection. Median OS was 8.8\u00a0months in all patients and 21.1\u00a0months in those with CR. Nine patients (48%) proceeded to allogeneic stem cell transplantation (allo\u2010SCT), four of those are still alive and in CR, accounting for a 5\u2010year survival rate of 55% of transplanted patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Cladribine, cytarabine, and idarubicin in relapsed AML is feasible and induces good response rates. As expected, infections are the most important complication. However, combined with allo\u2010SCT, long\u2010term survival can be achieved in a substantial number of patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13395","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T13:39:04Z","timestamp":1581514744000},"page":"538-545","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Long\u2010term follow\u2010up of Cladribine, high\u2010dose Cytarabine, and Idarubicin as salvage treatment for relapsed acute myeloid leukemia and literature review"],"prefix":"10.1111","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7223-9748","authenticated-orcid":false,"given":"Karin","family":"Mayer","sequence":"first","affiliation":[{"name":"Medizinische Klinik III, H\u00e4matologie\/Onkologie\/Rheumatologie Universit\u00e4tsklinikum Bonn Bonn Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinna","family":"Hahn\u2010Ast","sequence":"additional","affiliation":[{"name":"Medizinische Klinik III, H\u00e4matologie\/Onkologie\/Rheumatologie Universit\u00e4tsklinikum Bonn Bonn Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katjana","family":"Schwab","sequence":"additional","affiliation":[{"name":"Medizinische Klinik III, H\u00e4matologie\/Onkologie\/Rheumatologie Universit\u00e4tsklinikum Bonn Bonn Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo G. H.","family":"Schmidt\u2010Wolf","sequence":"additional","affiliation":[{"name":"Abteilung f\u00fcr Integrierte Onkologie Universit\u00e4tsklinikum Bonn Bonn Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Brossart","sequence":"additional","affiliation":[{"name":"Medizinische Klinik III, H\u00e4matologie\/Onkologie\/Rheumatologie Universit\u00e4tsklinikum Bonn Bonn Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Glasmacher","sequence":"additional","affiliation":[{"name":"Medizinische Klinik III, H\u00e4matologie\/Onkologie\/Rheumatologie Universit\u00e4tsklinikum Bonn Bonn Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"von Lilienfeld\u2010Toal","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin II Abteilung f\u00fcr H\u00e4matologie und Onkologie Universit\u00e4tsklinikum Jena Jena Germany"},{"name":"Leibniz\u2010Institut f\u00fcr Naturstoff\u2010Forschung und Infektionsbiologie Hans\u2010Kn\u00f6ll Institut Jena Germany"},{"name":"Center for Sepsis Control and Care (CSCC) Universit\u00e4tsklinikum Jena Jena Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,3,10]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1406184"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-017-0456-2"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2013.10.005"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(99)00087-9"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02551.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2774-z"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050239"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-003-0624-2"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.06.002"},{"issue":"4","key":"e_1_2_6_12_1","first-page":"385","article-title":"Cellular pharmacokinetics of 2\u2010chloro\u20102'\u2010deoxyadenosine nucleotides: comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients","volume":"1","author":"Liliemark J","year":"1995","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.1.256.256"},{"issue":"11","key":"e_1_2_6_14_1","first-page":"1842","article-title":"FLAG (fludarabine + high\u2010dose cytarabine + G\u2010CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias","volume":"8","author":"Visani G","year":"1994","journal-title":"Leukemia"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.8.2478"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.4.1237.1237"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.11.2804"},{"issue":"10","key":"e_1_2_6_18_1","first-page":"1563","article-title":"Clinical and laboratory studies of 2\u2010chlorodeoxyadenosine +\/\u2010 cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults","volume":"10","author":"Kornblau SM","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.10.3429.3429"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009053545"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.1286"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2003.00122.x"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-005-1046-0"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.00988.x"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1235274"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.036"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki221"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.09.002"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.09.016"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1996.tb01935.x"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058693"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050355"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.1.188"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.10.2216"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2013.917"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.22"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.13395","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13395","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13395","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13395","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T01:40:03Z","timestamp":1694050803000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,10]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1111\/ejh.13395"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13395","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"type":"print","value":"0902-4441"},{"type":"electronic","value":"1600-0609"}],"subject":[],"published":{"date-parts":[[2020,3,10]]},"assertion":[{"value":"2019-10-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}